Cell therapy technology specialist MaxCyte has teamed up with Ori Biotech to enhance the efficiency, scalability and productivity of the cell therapy manufacturing process.
Through this collaboration the companies will evaluate how MaxCyte's ExPERT platform, together with Ori's IRO technology, can optimise therapeutic cell yield and streamline the manufacturing timelines of primary T-cells.
The ExPERT platform is designed to offer efficient and scalable transfection capabilities, and has been used in more than 19 active clinical and commercial programmes thus far.
Meanwhile, the IRO platform is designed to optimise the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T-cells compared with traditional post-electroporation cell expansion.
To test the effectiveness of these platforms combined, Ori and MaxCyte have selected T-cells modified to CD19 CAR expression via CRISPR knock-in.
By combining the clinical-scale transfection capabilities of MaxCyte's technology with the automated fluid handling, customisable mixing of Ori's, the companies hope to enahnce cell cuture efficiency and scalability.
“By combining our respective strengths and technologies with Ori Biotech, we hope to significantly enhance the cell therapy manufacturing process," noted Maher Masoud, President and CEO of MaxCyte.
"Addressing the evolving demands of cell therapy manufacturing will ultimately accelerate the availability of transformative treatments for patients," he added.
Jason C. Foster, CEO of Ori Biotech, stated: “By integrating modular, best-of-breed technologies, we’re raising the standard of manufacturing by enhancing commercial viability.
"This collaboration will help bring cell therapies to patients faster, more reliably and at a greater scale," he concluded.